#H.I.G. Capital #London #United Kingdom #ITH Group Limited #aseptic compounding

H.I.G. Capital Acquires ITH Group Limited

On June 9, 2025, H.I.G. Capital, a globally recognized alternative investment firm managing $70 billion in capital, announced the successful acquisition of ITH Group Limited, a prominent UK provider of aseptic pharmaceutical compounding services. This strategic acquisition marks a significant step for H.I.G. as it expands its portfolio in the healthcare sector, aligning perfectly with its commitment to fostering growth in vital services.

ITH Group, founded in 2008, specializes in providing personalized injectable medications tailored to patients with specific medical requirements that conventional treatments may not sufficiently address. The company has established market-leading positions, particularly in chemotherapy, total parenteral nutrition, and central intravenous additive services. ITH also boasts a leading digital pharmacy that supplies essential, licensed medications to both private and National Health Service (NHS) patients across the UK.

In a collaborative effort with the company's founders, Adam Bloom and Karen Hamling, H.I.G. aims to maintain ITH’s impressive growth trajectory while exploring new initiatives, particularly in enhancing the production capabilities of the firm. The existing management team at ITH will remain intact, with Bloom serving as CEO and Hamling continuing as COO. Their leadership will be instrumental in driving the company’s future endeavors.

Adam Bloom remarked, “We are thrilled to have H.I.G. as a significant investor in ITH Group. Since our inception, we have focused on investing in our team and improving our services to better assist our patients. Today, we proudly uphold our status as a leading provider of compounding services in the UK, effectively supporting both the NHS and private healthcare sectors. We are committed to further diversifying our service offerings, enhancing our expertise in critical compounded medicines, and expanding our pharmacy services.”

John Harper, H.I.G.'s Managing Director and Head of the Europe Lower Middle Market LBO team, expressed his enthusiasm, stating, “We are excited to support Adam, Karen, and their team as they build upon ITH's existing success. The company’s reliable provision of compounded pharmaceuticals to both NHS and private customers in a market characterized by significant unmet demand, combined with H.I.G.'s proven history of supporting capacity growth in its portfolio companies, sets the stage for an exciting chapter in ITH's story.”

Gordon Cameron, the non-executive Chairman of ITH, lauded the management's achievements, stating, “Adam and Karen have established a robust business that delivers essential services to the UK healthcare sector, earning a commendable reputation for reliability through their unwavering focus on high-quality customer service. I look forward to joining this dynamic business under H.I.G.'s stewardship and contributing to its future growth.”

The acquisition underscores H.I.G.’s strategic interest in bolstering organizations that contribute crucial services to the healthcare landscape. With the ongoing pressures faced by the healthcare system, particularly regarding the supply of critical compounded medications, ITH’s services are more important than ever.

About ITH Group

ITH Group specializes in aseptic compounding services for both NHS and private patients, emphasizing chemotherapy, total parenteral nutrition, and central intravenous additive services. The company is based in London and is a key player in the UK’s healthcare ecosystem. For more information, visit ithgroup.uk.

About H.I.G. Capital

Founded in 1993, H.I.G. Capital is headquartered in Miami, with an international presence that includes offices in Atlanta, Boston, Chicago, Los Angeles, New York, San Francisco, and Stamford. The firm is dedicated to providing both debt and equity capital to middle-market companies, with a focus on operational improvements and value creation. H.I.G. has successfully invested in over 400 companies worldwide, positioning itself as a key player in the alternative investment space. For additional details, please refer to hig.com.